Home › Companies › VIR BIOTECHNOLOGY INC. › 2024-2025
Compiled from SEC Form N-PX filings and VIR BIOTECHNOLOGY INC.’s Form 8-K, filed 2025-05-29 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore VIR BIOTECHNOLOGY INC. in the interactive database Compare manager voting policies
These tallies are VIR BIOTECHNOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Jeffrey S. Hatfield | 93,985,116 | -- | -- | 10,933,739 | 12,050,291 | Majority: yes |
| Elect Director: Saira Ramasastry | 98,467,755 | -- | -- | 6,451,100 | 12,050,291 | Majority: yes |
| Proposal 2. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers. | 100,486,810 | 4,280,297 | 151,748 | -- | 12,050,291 | Majority: yes |
| Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's in | 116,311,775 | 162,660 | 494,711 | -- | 0 | Majority: yes |
Source: VIR BIOTECHNOLOGY INC., Form 8-K, filed with the SEC on 2025-05-29 — read the filing on EDGAR.
Each item below shows how the 231 asset managers that disclosed a VIR BIOTECHNOLOGY INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held 2025-05-29.
Combines 11 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Proposal 2. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”): 100,486,810 for, 4,280,297 against, per its Form 8-K filed 2025-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 138,063,698 outstanding shares: 73% for, 3% against (76% of the company cast a for/against vote).
The 228 asset managers below cast 96% of the shares they voted on this item FOR (93,403,550 for, 4,225,359 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 16,684,041 | 0 | 0 | 0 | For |
| BlackRock | 14,283,956 | 21,322 | 0 | 0 | For |
| ARCH Venture Management, LLC | 12,916,663 | 0 | 0 | 0 | For |
| Vanguard | 12,850,516 | 7,345 | 0 | 0 | For |
| State Street | 7,995,220 | 41,877 | 0 | 0 | For |
| Fidelity | 6,517,294 | 0 | 0 | 0 | For |
| Charles Schwab | 2,669,230 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,294,031 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 2,248,249 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 1,386,384 | 0 | 0 | Against |
| Dimensional | 1,274,142 | 0 | 0 | 0 | For |
| Artisan | 1,273,388 | 0 | 0 | 0 | For |
| Prudential/PGIM | 12,130 | 808,726 | 0 | 0 | Against |
| JPMorgan | 819,386 | 0 | 0 | 0 | For |
| Northern Trust | 633,613 | 829 | 0 | 0 | For |
| Clarius Group, LLC | 633,341 | 0 | 0 | 0 | For |
| Catalio Capital Management, LP | 611,608 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 605,297 | 0 | 0 | 0 | For |
| American Century | 513,980 | 0 | 0 | 0 | For |
| Woodline Partners LP | 466,737 | 0 | 0 | 0 | For |
| Renaissance | 466,118 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 459,337 | 0 | 0 | 0 | For |
| Invesco | 450,652 | 0 | 0 | 0 | For |
| Nuveen | 0 | 356,275 | 0 | 0 | Against |
| TIAA | 0 | 352,870 | 0 | 0 | Against |
Showing the 25 largest of 228 asset managers. See all 228 in the interactive database.
Meeting held 2025-05-29.
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Jeffrey S. Hatfield”): 93,985,116 for, 10,933,739 withheld, per its Form 8-K filed 2025-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 138,063,698 outstanding shares: 68% for, 8% withheld (76% of the company cast a for/withheld vote).
The 65 asset managers below cast 100% of the shares they voted on this item FOR (34,021,573 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,395,937 | 0 | 4,791 | 0 | For |
| BlackRock | 10,408,325 | 0 | 0 | 0 | For |
| Fidelity | 4,301,200 | 0 | 0 | 0 | For |
| State Street | 3,076,919 | 0 | 3,048 | 0 | For |
| Charles Schwab | 1,294,724 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 1,016,012 | 0 | Abstain |
| Aberdeen | 0 | 0 | 693,192 | 0 | Abstain |
| Artisan | 548,541 | 0 | 0 | 0 | For |
| JPMorgan | 380,390 | 0 | 0 | 0 | For |
| TIAA | 352,870 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 256,512 | 0 | Abstain |
| Equitable | 143,072 | 0 | 98,230 | 0 | For |
| PIMCO | 0 | 0 | 228,485 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 220,000 | 0 | Abstain |
| Prudential/PGIM | 201,717 | 0 | 12,130 | 0 | For |
| Jackson National | 0 | 0 | 205,661 | 0 | Abstain |
| Invesco | 0 | 0 | 183,182 | 0 | Abstain |
| Columbia Threadneedle | 182,507 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 166,318 | 0 | Abstain |
| Global X | 162,750 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,027 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 117,626 | 0 | Abstain |
| Putnam | 105,983 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 0 | 101,968 | 0 | Abstain |
| Principal | 0 | 0 | 89,621 | 0 | Abstain |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Meeting held 2025-05-29.
Combines 4 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Saira Ramasastry”): 98,467,755 for, 6,451,100 withheld, per its Form 8-K filed 2025-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 138,063,698 outstanding shares: 71% for, 5% withheld (76% of the company cast a for/withheld vote).
The 65 asset managers below cast 100% of the shares they voted on this item FOR (35,340,977 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,395,943 | 0 | 4,785 | 0 | For |
| BlackRock | 10,408,325 | 0 | 0 | 0 | For |
| Fidelity | 4,301,200 | 0 | 0 | 0 | For |
| State Street | 3,079,967 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 1,294,724 | 0 | Abstain |
| Dimensional | 0 | 0 | 1,016,012 | 0 | Abstain |
| Aberdeen | 693,192 | 0 | 0 | 0 | For |
| Artisan | 548,541 | 0 | 0 | 0 | For |
| JPMorgan | 380,390 | 0 | 0 | 0 | For |
| TIAA | 352,870 | 0 | 0 | 0 | For |
| American Century | 256,512 | 0 | 0 | 0 | For |
| Equitable | 143,072 | 0 | 98,230 | 0 | For |
| PIMCO | 228,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 220,000 | 0 | 0 | 0 | For |
| Prudential/PGIM | 201,717 | 0 | 12,130 | 0 | For |
| Jackson National | 189,862 | 0 | 15,799 | 0 | For |
| Invesco | 183,182 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 182,507 | 0 | 0 | 0 | For |
| Victory Capital | 166,318 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 162,750 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 150,027 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 117,626 | 0 | 0 | 0 | For |
| Putnam | 105,983 | 0 | 0 | 0 | For |
| BNY Mellon | 101,968 | 0 | 0 | 0 | For |
| Principal | 89,621 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Meeting held 2025-05-29.
Combines 3 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 116,311,775 for, 162,660 against, per its Form 8-K filed 2025-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 138,063,698 outstanding shares: 84% for, 0.2% against (84% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (38,003,426 for, 127 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,400,728 | 0 | 0 | 0 | For |
| BlackRock | 10,408,325 | 0 | 0 | 0 | For |
| Fidelity | 4,301,200 | 0 | 0 | 0 | For |
| State Street | 3,079,840 | 127 | 0 | 0 | For |
| Charles Schwab | 1,294,724 | 0 | 0 | 0 | For |
| Dimensional | 1,016,012 | 0 | 0 | 0 | For |
| Aberdeen | 693,192 | 0 | 0 | 0 | For |
| Artisan | 548,541 | 0 | 0 | 0 | For |
| JPMorgan | 380,390 | 0 | 0 | 0 | For |
| TIAA | 352,870 | 0 | 0 | 0 | For |
| American Century | 256,512 | 0 | 0 | 0 | For |
| Equitable | 241,302 | 0 | 0 | 0 | For |
| PIMCO | 228,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 220,000 | 0 | 0 | 0 | For |
| Prudential/PGIM | 213,847 | 0 | 0 | 0 | For |
| Jackson National | 205,661 | 0 | 0 | 0 | For |
| Invesco | 183,182 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 182,507 | 0 | 0 | 0 | For |
| Victory Capital | 166,318 | 0 | 0 | 0 | For |
| Global X | 162,750 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,027 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 117,626 | 0 | 0 | 0 | For |
| Putnam | 105,983 | 0 | 0 | 0 | For |
| BNY Mellon | 101,968 | 0 | 0 | 0 | For |
| Principal | 89,621 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Meeting held 2024-05-29 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Proposal 2. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”): 83,922,789 for, 22,639,307 against, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 138,063,698 outstanding shares: 61% for, 16% against (77% of the company cast a for/against vote).
The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 2,319 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| COLDSTREAM CAPITAL MANAGEMENT INC | 0 | 2,319 | 0 | 0 | Against |
| Echo45 Advisors LLC | 0 | 0 | 0 | 0 | -- |
Ranked by the number of VIR BIOTECHNOLOGY INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 138,063,698 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | SB INVESTMENT ADVISERS (UK) LTD | 12.08% |
| 2 | BlackRock | 10.36% |
| 3 | ARCH Venture Management, LLC | 9.36% |
| 4 | Vanguard | 9.31% |
| 5 | State Street | 5.82% |
| 6 | Fidelity | 4.72% |
| 7 | Charles Schwab | 1.93% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.66% |
| 9 | ORBIMED ADVISORS LLC | 1.63% |
| 10 | Aberdeen | 1.00% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| SVF Endurance (Cayman) Ltd. | 12.08% | DEF14A |
| BlackRock | 11.98% | 13F |
| Robert Nelsen | 9.83% | DEF14A |
| Entities affiliated with ARCH Venture Partners, L.P. | 9.36% | DEF14A |
| Vanguard Group | 9.28% | 13F |
| SB Investment Advisers (UK) Limited | 7.93% | 13G |
| Glaxo Group Limited | 6.19% | DEF14A |
| State Street | 4.15% | 13F |
| George Scangos, Ph.D. | 3.44% | DEF14A |
| Dimensional Fund Advisors | 1.94% | 13F |
Percentages above are of 138,063,698 shares outstanding, as reported by VIR BIOTECHNOLOGY INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VIR BIOTECHNOLOGY INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At VIR BIOTECHNOLOGY INC.'s shareholder meeting held 2025-05-29, in the 2024-2025 proxy season, 231 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,186 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VIR BIOTECHNOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-29.
VIR BIOTECHNOLOGY INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.